Clinical trials: Tri-specific Killer Engager
Tri-specific Killer Engager, Solid Tumor
GTB-5550 in Advanced Solid Tumors
This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers.
- Conditions
- Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
- Trial name
- NCT07541573
- Testing
- GTB-5550
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Masonic Cancer Center, University of Minnesota